.

Deeper Knowledge, Faster

  • Predict branded drug patent expiration
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Cipla
Cerilliant
AstraZeneca
Cantor Fitzgerald
Express Scripts
Daiichi Sankyo
Accenture
US Army
Deloitte
UBS

Generated: June 28, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022187

« Back to Dashboard
NDA 022187 describes INTELENCE, which is a drug marketed by Janssen R And D and is included in one NDA. It is available from three suppliers. There are four patents protecting this drug. Additional details are available on the INTELENCE profile page.

The generic ingredient in INTELENCE is etravirine. There are five drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the etravirine profile page.

Summary for NDA: 022187

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:1
Formulation / Manufacturing:see details

Pharmacology for NDA: 022187

Suppliers and Packaging for NDA: 022187

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
INTELENCE
etravirine
TABLET;ORAL 022187 NDA State of Florida DOH Central Pharmacy 53808-0787 53808-0787-1 30 TABLET in 1 BLISTER PACK (53808-0787-1)
INTELENCE
etravirine
TABLET;ORAL 022187 NDA Physicians Total Care, Inc. 54868-5864 54868-5864-0 120 TABLET in 1 BOTTLE, PLASTIC (54868-5864-0)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength100MG
Approval Date:Jan 18, 2008TE:RLD:Yes
Patent:7,887,845Patent Expiration:Mar 25, 2019Product Flag?YSubstance Flag?Delist Request?
Patent:8,003,789Patent Expiration:Nov 1, 2019Product Flag?YSubstance Flag?YDelist Request?
Patent:6,878,717Patent Expiration:Nov 5, 2019Product Flag?Substance Flag?Delist Request?
Patented Use:COMBO W/ OTHER ANTIRETROVIRALS FOR TX OF HIV-1 IN ANTIRETROVIRAL TX-EXPERIENCED PT 6 YEARS UP, WHO HAVE EVIDENCE OF VIRAL REPLICATION AND HIV-1 STRAINS RESISTANT TO NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR AND OTHERANTIRETROVIRALS


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Novartis
Covington
US Department of Justice
Citi
Harvard Business School
Medtronic
Federal Trade Commission
Merck
Queensland Health
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot